Caribou Biosciences
CRBU
104 hedge funds and large institutions have $313M invested in Caribou Biosciences in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 18 reducing their positions, and 11 closing their positions.
139% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 18
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
88% more call options, than puts
Call options by funds: $352K | Put options by funds: $187K
12% more funds holding
Funds holding: 93 → 104 (+11)
4.61% more ownership
Funds ownership: 51.61% → 56.22% (+4.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less capital invested
Capital invested by funds: $465M → $313M (-$151M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$8.09M |
| 4 |
JP Morgan Chase
New York
|
+$5.24M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.8M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$10.9M |
| 3 |
Coatue Management
New York
|
-$8.41M |
| 4 |
CCM
CloudAlpha Capital Management
Hong Kong
|
-$6.26M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.23M |
CRBU Hedge Fund Activity: Q1 2022 in Review
104 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q1 2022, worth a combined $313M — down 33% from $465M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CRBU positions and 11 closed out — a net gain of 12 holders — while 43 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $16.4M. The largest seller was Fidelity Investments, cutting an estimated $13.8M.
- 104 institutional investors held Caribou Biosciences (CRBU) as of Q1 2022, up from 93 in Q4 2021.
- Funds reported $313M of Caribou Biosciences stock for Q1 2022, down 33% quarter-over-quarter.
- 23 funds opened new Caribou Biosciences positions in Q1 2022 and 11 closed out, a net change of +12 holders.
- The largest Caribou Biosciences buyer in Q1 2022 was BlackRock, an estimated $16.4M added.
- The largest Caribou Biosciences seller in Q1 2022 was Fidelity Investments, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2022.